ABZENA ORD GBP0.002 overview

Abzena partners with FDA on publication demonstrating the benefits of the MAPPs assay for immunogenicity PR Newswire SAN DIEGO, Dec. 19, 2023 SAN DIEGO , Dec. 19, 2023 /PRNewswire/ -- Abzena, the leading end-to-end CDMO for complex biologics and bioconjugates, has co-authored a publication with the US Food and Drug Administration (FDA) demonstrating the potential of the MHC Associated Peptide Proteomics (MAPPs) assay as an important method to interrogate immunogenicity risk and help design...

Abzena Selects IPS for Turnkey Delivery of Their New CGMP Facility in North Carolina PR Newswire BLUE BELL, Pa., June 1, 2022 BLUE BELL, Pa. , June 1, 2022 /PRNewswire/ -- IPS-Integrated Project Services, LLC , a leading provider of engineering, procurement, construction management, and validation (EPCMV) services, announces its support to Abzena ( North Carolina ) LLC to perform full design, construction management, and CQV services for their new monoclonal antibody (mAb) facility in Sanford,...

FORM 8.3 PUBLIC DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1. KEY INFORMATION (a) Full name of discloser: Invesco Ltd. acting in concert with IP Group plc (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of offeror/offeree in...